Cross-education of Skill and Strength in Healthy People Subjected to an Upper-limb Disuse Model (IMMO-CROSS)

May 22, 2026 updated by: Iván Alejandro Cuyul Vásquez, Universidad Catolica de Temuco

Cross-education of Skill and Strength Through Contralateral Manual Dexterity Training in Healthy Young Adults Subjected to an Upper-limb Disuse Model: A Randomized Controlled Trial.

This randomized controlled trial aims to compare manual dexterity and strength between a group undergoing a contralateral manual dexterity training program and a no-intervention control group in healthy, physically inactive individuals subjected to an induced upper-limb disuse model.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Not yet recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

Cross-education of skill offers promising opportunities for the rehabilitation of upper-limb musculoskeletal injuries. An approach based on contralateral manual dexterity training could accelerate functional recovery, reduce motor skill loss during periods of immobilization, and optimize conventional rehabilitation protocols. However, controlled studies are needed to analyze the efficacy of specific unilateral training protocols designed to maximize cross-education before clinical translation. To date, no experimental studies have been published on healthy individuals subjected to upper-limb disuse models alongside contralateral skill training involving functional tasks. This cross-education effect could potentially prevent the loss of manual dexterity and strength that occurs during immobilization. For this research, a contralateral manual dexterity training protocol was developed based on the functional limitations commonly experienced by individuals with forearm and hand musculoskeletal injuries (e.g., distal radius fractures, wrist sprains, carpal tunnel syndrome, and tendinopathies). Additionally, the protocol incorporates characteristics from training programs that have demonstrated the greatest cross-education effect.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
34

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.
  • Name: Iván A. Cuyul-Vásquez, PhD(c)
  • Phone Number: +56452205205
  • Email: icuyul@uct.cl

Study Locations

  • Chile
    • Araucania
      • Temuco, Araucania, Chile, 4813302
        • UCT, Facultad de ciencias de la Salud
        • Contact:
          • Iván A. Cuyul-Vásquez, PhD(c)
          • Phone Number: +56452205205
          • Email: icuyul@uct.cl
        • Contact:
          • Cuyul-Vásquez Iván Cuyul-Vásquez, PhD(C)
          • Phone Number: +56452205205
          • Email: icuyul@uct.cl

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Individuals will be eligible for inclusion if they are right-handed adults aged 18 to 35 years with a body mass index (BMI) between 18.5 and 30 kg/m².
  • Individuals must be classified as physically inactive, defined as not meeting the World Health Organization criteria of at least 150 minutes of moderate-intensity physical activity or 75 minutes of vigorous-intensity physical activity per week.

Exclusion Criteria:

  • Individuals who have engaged in physical training (e.g., any form of strength or aerobic exercise) or specific manual dexterity training within the past 6 months. - Individuals who regularly participate in artistic, occupational, or sporting activities requiring high levels of manual dexterity (e.g., musicians, gamers, craftspeople).
  • Individuals with a history of orthopedic or traumatic injuries affecting either upper extremity. Individuals with pathologies or conditions that preclude safe training (e.g., uncontrolled hypertension, or visual, auditory, or cognitive impairments [for example, dyscalculia]).
  • Individuals currently using nutritional supplements or medications that interfere with the regulation of skeletal muscle mass and strength (e.g., whey protein, creatine) or the central nervous system (e.g., antidepressants, anxiolytics, hypnotics).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Contralateral manual dexterity training
Participants in the experimental group will perform contralateral manual dexterity training focused on moving 0.5, 1.0, or 1.5 kg cylinders using different grips and movements across various planes on a gridded board. Participants will execute various grips to place the cylinders into the quadrants indicated on a smartphone screen.
Other: Contralateral Manual Dexterity Training
The subjects in the experimental group will perform contralateral manual dexterity training focused on moving cylinders of 0.5, 1 or 1.5 kilos with grips and movements in different planes on a gridded board. Participants will have to develop different grips and place the cylinders in the quadrants indicated on a smartphone screen.
No Intervention: Control group without intervention

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Fine Manual Dexterity
Time Frame: Baseline and day 7
Fine manual dexterity will be assessed using the Functional Dexterity test (FDT). Using a stopwatch, the evaluator records the total time in seconds that the participant takes to complete the task.
Baseline and day 7
Force control
Time Frame: Baseline and day 7
In a seated position with the elbow flexed, participants will perform isometric contractions to reach a target torque guided by real-time visual feedback. The accuracy of maintaining these contractions in the wrist flexor and extensor muscles will be assessed using a Humac Norm isokinetic dynamometer (Computer Sports Medicine, Inc., Stoughton, MA, USA). Participants will perform a continuous 60-second isometric contraction exercise. During this period, participants will adjust their force level to between 10% and 30% of their maximum voluntary contraction (MVC) at 10-second intervals. Three attempts will be performed per limb. The Root Mean Square Error (RMSE) will be recorded.
Baseline and day 7
Gross Manual Dexterity
Time Frame: Baseline and day 7
This gross manual dexterity will be assessed using the same task performed during the experimental group's contralateral manual dexterity training. Specifically, participants will complete 15 trials, moving cylinders of varying weights across a gridded board following a sequence displayed on a smartphone. The time required to complete these 15 trials will be recorded.
Baseline and day 7

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Handgrip strength
Time Frame: Baseline and day 7
Maximum lumbrical and cylindrical grip strength will be assessed using a Jamar Plus+ digital hand dynamometer. The highest value from three attempts will be recorded for each assessment
Baseline and day 7
Joint Position Sense Test
Time Frame: Baseline and day 7
Proprioception: Wrist flexion-extension joint position sense will be assessed using the Joint Position Sense Test (JPST). All measurements will be conducted with a Humac Norm isokinetic dynamometer (Computer Sports Medicine, Inc., Stoughton, MA, USA). Three attempts will be made per limb. The absolute error (difference in degrees between 30° and the angle achieved during the test) will be recorded.
Baseline and day 7
Left/right judgment
Time Frame: Baseline and day 7
Left/right judgment will be assessed using the Recognise™ application (Noigroup, Adelaide, Australia). Performance on the laterality judgment task was quantified using the Inverse Efficiency Score (IES), calculated as the average reaction time of correct responses divided by the proportion of correct responses (IES = RT / PC). 3 blocks of 20 images (60 images total). Maximum exposure time: 5 seconds per image.
Baseline and day 7

Other Outcome Measures

Other Outcome Measures

For clinical trials, a planned measurement described in the protocol that is used to determine the effect of an intervention/treatment on participants. For observational studies, a measurement or observation that is used to describe patterns of diseases or traits, or associations with exposures, risk factors, or treatment. Types of outcome measures include primary outcome measure and secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Physical activity level
Time Frame: Baseline and day 7
Weekly metabolic equivalents (MET-min/week) will be calculated using the validated Spanish version of the Global physical activity questionnaire (GPAQ).
Baseline and day 7
Psychological Distress
Time Frame: Baseline
Psychological Distress, including symptoms of depression, anxiety, and stress, will be assessed using the 21-item Depression, Anxiety and Stress Scale (DASS-21). This self-report instrument will be used to quantify the severity of emotional distress across these three domains. This scale has a minimum score of 0 and a maximum of 126 points (total score calculated by doubling the sum of the 21 items). Higher scores in DASS-21 indicate greater psychological distress.
Baseline
Sleep Quality:
Time Frame: Baseline
Sleep disturbances and overall sleep quality will be assessed using the Pittsburgh Sleep Quality Index (PSQI). This scale has a minimum score of 0 and a maximum of 21 points (higher scores indicate worse sleep quality)
Baseline
Daily steps
Time Frame: During 7 days of immobilization
Physical activity will be monitored using a Xiaomi Band 9 smartwatch (number of daily steps), which participants will wear throughout the seven-day mobilization period.
During 7 days of immobilization
Sleep time
Time Frame: During 7 days of immobilization
Sleep time will be measured using a Xiaomi Band 9 smartwatch (hours), which participants will wear throughout the seven-day immobilization period.
During 7 days of immobilization

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Universidad Catolica de Temuco

Collaborators

Collaborators

An organization other than the sponsor that provides support for a clinical study. This support may include activities related to funding, design, implementation, data analysis, or reporting.
University of Valencia
Universidad de La Frontera

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
May 25, 2026

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
October 1, 2026

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
January 30, 2027

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
May 14, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
May 22, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
May 29, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
May 29, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
May 22, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
May 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • INMO-CROSS-2026

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Immobilization

Clinical Trials on Contralateral Manual Dexterity Training

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings